AR066155A1 - Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia - Google Patents
Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapiaInfo
- Publication number
- AR066155A1 AR066155A1 ARP080102438A ARP080102438A AR066155A1 AR 066155 A1 AR066155 A1 AR 066155A1 AR P080102438 A ARP080102438 A AR P080102438A AR P080102438 A ARP080102438 A AR P080102438A AR 066155 A1 AR066155 A1 AR 066155A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- nhc
- conh
- nhso2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Los compuestos de formula (1) poseen una afinidad de enlace significativamente baja con receptores tiroideos y por lo tanto carecen de manera considerable de efectos tirotoxicos. También se refiere al uso del compuesto de formula (1) para la preparacion de un medicamento para tratar diversas afecciones patologicas tales como obesidad, dislipidemia, síndrome metabolico y co-morbilidades asociadas con síndrome metabolico. Reivindicacion 1: Un compuesto de formula (1) donde, R1 y R3 son iguales o diferentes y son seleccionados de manera independiente de H, alquilo C1-6, cicloalquilo C3-7, halo, CN, CF3, -O-alquilo C1-6, -CO2-alquilo C1-6, -COOH, -CONH-alquilo C1-6, -CONH-arilo, -NH2, -CONH-R6, -CONR5, -alquil C1-3-arilo, -alquilo C1-3-R6, -NH-alquilo C1-6, -NH-arilo, -NH-SO2-alquilo C1-6, -CH2NH-alquilo C1-6, -CH2-O-alquilo C1-6, -alquil C1-3-NR5, R6, R7, donde alquilo C1-6 y cicloalquilo C3-7 están sustituidos en forma opcional con uno o mas sustituyentes seleccionados de alquilo C1-6, halo, ciano, -OH, oxo, -COOH, -O-alquilo C1-6, -O-bencilo, -COO-alquilo C1-6, -CONH-alquilo C1-6, -CONR5, -CONH-arilo, -CONH-heteroarilo o -CH2NR5; R2 se selecciona de alquilo C1-6, cicloalquilo C3-6, alquenilo C3-6, alquinilo C3-6, -C(O)-alquil C1-3-COOH, -alquil C1-3-COOH, -C(O)-alquil-C1-3-COO-alquilo, -C(O)-C(O)O-alquilo C1-6, -C(O)-alquil- C1-3-NH-alquilo C1-6, -C(O)-O-alquilo C1-6, -C(O)NR5, -C(O)NH-alquilo C1-6, -C(O)-alquilarilo C1-3, -C(O)-alquil C1-3-R6, R6, R7, donde dicho alquilo C1-6, cicloalquilo C3-6, alquenilo C3-6, alquinilo C3-6 están sustituidos en forma opcional con uno o más sustituyentes seleccionados de perhaloalquilo, oxo, -C(O)OH, -C(O)-O-alquilo C1-3, -C(O)-O-alquil C1-3-arilo, -C(O)-O-alquil C1-3-R6, -CONH2, -CONH-alquilo C1-3, -C(O)NH-arilo, -C(O)NH-R6, -CONR5, -CONHNH2, -C(=NH)NH-alquilo C1-6, -C(=NH)NH2, C(=NH)NHOH, -C(O)-R8, -C(O)NHSO2-alquilo C1-6, -C(O)NHSO2-arilo, -C(O)NHOH, -C(O)NHSO2-R6, -C(O)NHNH-alquilo C1-6, -C(O)NHNH-arilo, -CONH-alquil C1-2-arilo, -C(O)NH-alquil C1-2-R6, -CH2NR5, -NH2, -NH-alquilo C1-6, -NH-C(O)-O-alquilo C1-3, -NH-C(O)-alquilo C1-3, -NHC(O)-arilo, -NHC(O)-alquilarilo C1-3, -NHC(O)-R6, -NH-C(O)NR5, -NH-C(O)NH-arilo, -NHC(O)NH-alquilo C1-6, -NHSO2-alquilo C1-6, -NH-SO2-arilo, -NH-SO2-R6, halo, ciano, -OH, -O-alquilo C1-6, -O-arilo, -O-heteroarilo, -O-alquil-C1-2-arilo, -SO3H, -SO2NH-arilo, -SO2NH-R6 o -SO2NH-alquilo C1-6, R6 o R7; R5 junto con el átomo de nitrogeno al que está unido forman un anillo saturado o insaturado de C3-6 miembros, que puede contener además 1-2 heteroátomos seleccionados de O, N o S y puede estar sustituido opcionalmente con uno o más sustituyentes seleccionados de oxo, -COOH, halo, -OH, -O-alquilo C1-6, o -alquilo C1-6; R6 se selecciona de fenilo o heteroarilo de 5-8 miembros que contiene 1-4 heteroátomos seleccionados de O, N o S, donde dicho anillo heteroarilo o fenilo están sustituidos en forma opcional con uno o más sustituyentes seleccionados de halogeno, -OH, -O-alquilo C1-6, -perhaloalquilo, -alquilo C1-6, -cicloalquilo C3-6, -SO2-alquilo C1-6, ciano, -COOH, -C(O)O-alquilo C1-6, -C(O)O-CH2-arilo, -C(O)O-arilo, -CONH-alquilo C1-3, nitro, -NH2, -NH-alquilo C1-6, -NHC(O)-alquilo C1-6, -NHC(O)-arilo, -NHSO-alquilo C1-6, -CONH2, -SO2-alquilo C1-6, -NHSO2-alquilo C1-6 o -COR8; R7 es un anillo heterocíclico de 3-6 miembros que contiene 1-4 heteroátomos seleccionados de O, N o S, y el mencionado anillo heterocíclico está sustituido opcionalmente con uno o más sustituyentes seleccionado de oxo, halogeno, -O-alquilo C1-6, -OH, -CF3, alquilo C1-6, cicloalquilo C3-6, ciano, -COOH, -C(O)O-alquilo C1-6, -C(O)O-CH2-arilo, -C(O)O-arilo, -NH2, -NH-alquilo C1-6, -NHC(O)-alquilo C1-6, -NHC(O)-arilo, -CONH2, -SO2-arilalquilo C1-6, -SO2-alquilo C1-6, -NHSO2-alquilo C1-6 o -COR8; R8 es un aminoácido que está enlazado a través de su átomo de nitrogeno; Z = O, CH2 o NH; R4 se selecciona de las formulas P, Q o T; R9 se selecciona de -OH, -O-alquilo, -OSO3H, halogeno, -C(O)O-alquilo C1-6, -C(O)NHR8, -OC(O)-alquilo C1-6, -O-perhaloalquilo, -OC(O)O-alquilo C1-6, -CONR5 , -NHCO-alquilo C1-6, -NHC(O)-O-alquilo C1-6, -NHC(O)-O-arilo, -NHSO2-alquilo C1-6, -NHSO2-arilo, -NHCONR5 o de formula (2); R10 se selecciona de H, halogeno, alquilo C1-6, alcoxi, ariloxi, -NHCO-alquilo C1-6, -NHSO2-alquilo C1-6 o -NH-SO2-arilo; R11 es -CO-alquilo C1-6, -SO2-alquilo C1-6 o -SO2-arilo; G' se selecciona de H, halogeno o alquilo C1-6; G'' se selecciona de hidrogeno, alquilo C1-6, cicloalquilo C3-6, arilo, halogeno, perhaloalquilo, CN, CHO, -alquilarilo-C1-3, -alquil C1-6-O-alquilo C1-6, -CH2R9, -CH2-arilo, -CH2NR5, -COOH, -C(O)O-alquilo C1-6, -CONH-alquilo C1-6, -CONR5, -SO2NR5, -SO2NH-alquilo C1-6, -SO2NH-arilo; n puede ser uno o dos; incluyendo sus sales aceptables para uso farmacéutico y sus hidratos, solvatos, atropisomeros, regioisomeros, enantiomeros, diasteromeros, tautomeros, polimorfos y profármacos de los mismos, con la salvedad que: cuando R4 es Q entonces R2 es diferente de R6 y R7; incluyendo sus sales aceptables para uso farmacéutico y sus hidratos, solvatos, atropisomeros, regioisomeros, enantiomeros, diasteromeros, tautomeros, polimorfos y profármacos de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN857KO2007 | 2007-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR066155A1 true AR066155A1 (es) | 2009-07-29 |
Family
ID=39828965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080102438A AR066155A1 (es) | 2007-06-06 | 2008-06-06 | Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia |
Country Status (27)
Country | Link |
---|---|
US (2) | US8143424B2 (es) |
EP (1) | EP2061766B1 (es) |
JP (1) | JP5243537B2 (es) |
KR (1) | KR101152965B1 (es) |
CN (1) | CN101772487B (es) |
AR (1) | AR066155A1 (es) |
AT (1) | ATE478053T1 (es) |
AU (1) | AU2008259314B2 (es) |
CA (1) | CA2698704C (es) |
CY (1) | CY1110925T1 (es) |
DE (1) | DE602008002205D1 (es) |
DK (1) | DK2061766T3 (es) |
EA (1) | EA019084B1 (es) |
ES (1) | ES2351274T3 (es) |
HK (1) | HK1129221A1 (es) |
HR (1) | HRP20100611T1 (es) |
IL (1) | IL202515A (es) |
MX (1) | MX2009013070A (es) |
NZ (1) | NZ582273A (es) |
PL (1) | PL2061766T3 (es) |
PT (1) | PT2061766E (es) |
RS (1) | RS51501B (es) |
SI (1) | SI2061766T1 (es) |
TW (1) | TWI360541B (es) |
UA (1) | UA98962C2 (es) |
WO (1) | WO2008149379A2 (es) |
ZA (1) | ZA200908760B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9724381B2 (en) * | 2009-05-12 | 2017-08-08 | The Administrators Of The Tulane Educational Fund | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
AU2011240367B2 (en) * | 2010-04-15 | 2015-07-16 | Merck Patent Gmbh | Process for the preparation of hydroquinones |
WO2011140333A1 (en) * | 2010-05-07 | 2011-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | Identification of stabilizers of multimeric proteins |
CA2884481C (en) | 2012-09-17 | 2021-04-27 | Madrigal Pharmaceuticals, Inc. | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
KR102153772B1 (ko) | 2013-09-09 | 2020-09-09 | 펠로톤 테라퓨틱스, 인크. | 아릴 에테르 및 이의 용도 |
US9884843B2 (en) | 2013-12-16 | 2018-02-06 | Peloton Therapeutics, Inc. | Cyclic sulfone and sulfoximine analogs and uses thereof |
CN103992225B (zh) * | 2014-03-26 | 2016-01-13 | 安徽师范大学 | 一种水杨醛衍生物及其制备方法 |
JP6543342B2 (ja) | 2014-08-14 | 2019-07-10 | アルハマドシャー,マモウン,エム. | 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション |
JP6626885B2 (ja) * | 2014-10-31 | 2019-12-25 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 新しいピリジニルオキシ及びフェニルオキシピラゾリル化合物 |
WO2016144826A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
WO2016145045A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions for use in treating glioblastoma |
US10807948B2 (en) | 2015-03-11 | 2020-10-20 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
US10278942B2 (en) | 2015-03-11 | 2019-05-07 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
WO2016168510A1 (en) | 2015-04-17 | 2016-10-20 | Peloton Therapeutics, Inc. | Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
US20180230103A1 (en) * | 2015-11-16 | 2018-08-16 | Lonza Ltd | Method for preparation of 1-methyl-3-(trifluoromethyl)-1h-pyrazol-5-ol |
RU2621163C1 (ru) * | 2016-02-16 | 2017-05-31 | государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) | Антифибролитическое средство |
IL302336A (en) | 2016-10-18 | 2023-06-01 | Madrigal Pharmaceuticals Inc | Methods for treating liver disorders or lipid disorders using a THR-BETA agonist |
NZ755597A (en) | 2017-02-17 | 2023-06-30 | Eidos Therapeutics Inc | Processes for preparing ag-10, its intermediates, and salts thereof |
WO2019183463A1 (en) | 2018-03-23 | 2019-09-26 | Eidos Therapeutics, Inc. | Methods of treating ttr amyloidosis using ag10 |
MA53238A (fr) | 2018-08-17 | 2022-04-13 | Eidos Therapeutics Inc | Formules d'ag10 |
EP3853209A4 (en) | 2018-09-22 | 2022-09-14 | Torrent Pharmaceuticals Limited | METHODS FOR THE PRODUCTION OF PYRAZOLE COMPOUNDS |
WO2020175957A1 (ko) * | 2019-02-28 | 2020-09-03 | 주식회사 마더스제약 | 피라졸 아마이드 유도체 화합물 및 이의 용도 |
WO2023047203A1 (en) | 2021-09-25 | 2023-03-30 | Torrent Pharmaceuticals Ltd | Combination of omzotirome and antidiabetic agent, antihypertensive agent or anti-dyslipidemic agent |
WO2023164538A1 (en) * | 2022-02-23 | 2023-08-31 | Biohaven Therapeutics Ltd. | Pyrazolyl compounds as kv7 channel activators |
WO2023164537A1 (en) * | 2022-02-23 | 2023-08-31 | Biohaven Therapeutics Ltd. | Pyrazolyl compounds as kv7 channel activators |
WO2023164536A1 (en) * | 2022-02-23 | 2023-08-31 | Biohaven Therapeutics Ltd. | Pyrazolyl compounds as kv7 channel activators |
CN114920635B (zh) * | 2022-04-29 | 2023-05-12 | 郑州原理医药研究院有限公司 | 4-羟基-1-茚酮的制备方法 |
WO2023247552A1 (en) | 2022-06-21 | 2023-12-28 | Syngenta Crop Protection Ag | Microbiocidal bicyclic heterocyclic carboxamide derivatives |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7598596A (en) | 1995-11-01 | 1997-05-22 | Allergan, Inc. | Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity |
DK0863136T3 (da) | 1997-02-25 | 2004-02-02 | Akzo Nobel Nv | Azetidin- og pyrrolidinderivater |
RU2198873C2 (ru) | 1998-02-26 | 2003-02-20 | Акцо Нобель Н.В. | Производные азетидина и пирролидина |
US6240678B1 (en) | 1998-07-09 | 2001-06-05 | Karl Heinz Spether | Capping head with torque adjustment |
PL364802A1 (en) | 1999-03-01 | 2004-12-13 | Pfizer Products Inc. | Oxamic acids and derivatives as thyroid receptor ligands |
CA2374262A1 (en) | 1999-06-01 | 2000-12-07 | The University Of Texas Southwestern Medical Center | Method of treating hair loss |
EP1127882A1 (en) | 2000-01-25 | 2001-08-29 | Pfizer Products Inc. | Tetrazole compounds as thyroid receptor ligands |
US6620830B2 (en) | 2000-04-21 | 2003-09-16 | Pfizer, Inc. | Thyroid receptor ligands |
ES2330089T3 (es) | 2001-08-17 | 2009-12-04 | Mitsui Chemicals Agro, Inc. | Derivado de 3-fenoxi-4-piridazinol y composicion herbicida que lo contiene. |
WO2003064369A1 (fr) | 2002-01-30 | 2003-08-07 | Kissei Pharmaceutical Co., Ltd. | Nouveau ligand de recepteur de l'hormone thyroidienne, preparations medicinales le contenant et leur utilisation |
US6747048B2 (en) | 2002-05-08 | 2004-06-08 | Bristol-Myers Squibb Company | Pyridine-based thyroid receptor ligands |
US7230025B2 (en) | 2002-09-26 | 2007-06-12 | Pfizer, Inc. | Pyrazole derivatives |
ITRM20030363A1 (it) * | 2003-07-24 | 2005-01-25 | Fernando Goglia | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse. |
MX2007014501A (es) | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos novedosos que contienen acido fosfinico. |
GB0513692D0 (en) * | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
CA2614529C (en) * | 2005-07-21 | 2011-06-28 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives as thyroid hormone receptor agonists |
WO2007027842A1 (en) | 2005-08-31 | 2007-03-08 | Bayer Healthcare Llc | Anilinopyrazole derivatives useful for the treatment of diabetes |
-
2008
- 2008-06-02 MX MX2009013070A patent/MX2009013070A/es active IP Right Grant
- 2008-06-02 EA EA200901651A patent/EA019084B1/ru not_active IP Right Cessation
- 2008-06-02 RS RSP-2010/0491A patent/RS51501B/en unknown
- 2008-06-02 NZ NZ582273A patent/NZ582273A/en not_active IP Right Cessation
- 2008-06-02 CA CA2698704A patent/CA2698704C/en active Active
- 2008-06-02 US US12/224,168 patent/US8143424B2/en not_active Expired - Fee Related
- 2008-06-02 SI SI200830091T patent/SI2061766T1/sl unknown
- 2008-06-02 PL PL08772567T patent/PL2061766T3/pl unknown
- 2008-06-02 DE DE602008002205T patent/DE602008002205D1/de active Active
- 2008-06-02 WO PCT/IN2008/000345 patent/WO2008149379A2/en active Application Filing
- 2008-06-02 ES ES08772567T patent/ES2351274T3/es active Active
- 2008-06-02 AU AU2008259314A patent/AU2008259314B2/en not_active Ceased
- 2008-06-02 UA UAA200913974A patent/UA98962C2/ru unknown
- 2008-06-02 EP EP08772567A patent/EP2061766B1/en active Active
- 2008-06-02 PT PT08772567T patent/PT2061766E/pt unknown
- 2008-06-02 JP JP2010510961A patent/JP5243537B2/ja active Active
- 2008-06-02 AT AT08772567T patent/ATE478053T1/de active
- 2008-06-02 CN CN200880102100.8A patent/CN101772487B/zh active Active
- 2008-06-02 KR KR1020107000236A patent/KR101152965B1/ko active IP Right Grant
- 2008-06-02 DK DK08772567.7T patent/DK2061766T3/da active
- 2008-06-06 TW TW097121081A patent/TWI360541B/zh active
- 2008-06-06 AR ARP080102438A patent/AR066155A1/es active IP Right Grant
-
2009
- 2009-07-21 HK HK09106665.2A patent/HK1129221A1/xx not_active IP Right Cessation
- 2009-12-03 IL IL202515A patent/IL202515A/en active IP Right Grant
- 2009-12-09 ZA ZA200908760A patent/ZA200908760B/xx unknown
-
2010
- 2010-11-11 HR HR20100611T patent/HRP20100611T1/hr unknown
- 2010-11-18 CY CY20101101041T patent/CY1110925T1/el unknown
-
2012
- 2012-01-10 US US13/346,968 patent/US8378118B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR066155A1 (es) | Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia | |
PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
PE20190329A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
AR059516A1 (es) | Derivados de isoxazolina, procesos de obtencion y composiciones herbicidas | |
AR068057A1 (es) | Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio. | |
PE20070172A1 (es) | DERIVADOS BICICLICOS COMO INHIBIDORES DE p38 | |
PE20151951A1 (es) | Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
PE20212247A1 (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos | |
CO6321244A2 (es) | Pirrolopiridinas como inhibidores de cinasa | |
AR077977A1 (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
AR092568A1 (es) | Derivados triciclicos de quinolinas y de quinoxalinas | |
PE20151981A1 (es) | Pontenciador de inhibidores del homologo de zeste | |
AR066043A1 (es) | Derivados de benzamida sustituida como inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa tipo 1(11betahsd1) | |
AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
DE602006006850D1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
PE20121048A1 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
AR044005A1 (es) | Compuestos biciclicos, procedimiento para su preparacion, su uso para preparar un medicamento y composiciones farmaceuticas que los comprenden | |
AR079486A1 (es) | Compuestos heterociclicos nitrogenados de oxima, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades proliferativas. | |
EA201170096A1 (ru) | Замещенные производные пиримидона | |
RS52812B (en) | PYROLIDIN-2-DERIVATIVES AS MODULATORS OF ANDROGENIC RECEPTORS | |
AR090670A1 (es) | Compuestos herbicidas | |
AR077463A1 (es) | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias | |
AR067058A1 (es) | Oxazolidinonas sustituidas y su uso para preparar medicamentos | |
AR057433A1 (es) | Compuestos quimicos derivados de piridopirimidina, un metodo para su preparacion y composicion farmaceutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |